Sickle Cell Disease PBMC
About: Sickle Cell Disease PBMC samples are collected from clinically confirmed sickle cell disease donors and cryopreserved. These PBMCs are ideal for studying immune dysregulation, inflammation, and investigating potential therapeutic interventions.
| Lot # | Condition | Cell Count (M) | Race/Ethnicity | Age | Gender | Country of Collection | Medications | Vials | Price | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| 75833 | Sickle Cell Disease/Anemia | 10M | African American | 27 | Female |
Adakveo IV Q other Month Hydroxyurea 1500 mg QD Folic Acid 1 mg QD Oxycodone 30 mg Q3-4 hr PRN Oxycotin 15 mg Q12 PRN Albuterol inh PRN
|
6 | $765.00 | ||
| 74014 | Sickle Cell Disease/Anemia | 10M | African American | 39 | Male | United States (US) |
Folic Acid/2mg/QD - Started: 2001 Ibuprofen/800mg/Every 8 hours - Started: 2010 Promethazine/25mg/PRN -Started: 2010 for nausea Morphine Sulfate IR/30mg/every 4 hours - Started: 2022 cetirizine/10mg/PRN - Started: 2015 allergies OxyContin/60mg/Every 8 hours Nexium/PRN OxyContin/15mg/Every 8 hours Lisinopril 25 mg QD
|
2 | $765.00 | |
| 73122 | Sickle Cell Disease/Anemia | 10M | African American | 53 | Female | United States (US) |
folic acid, 1MG, QD hydroxyurea, 500mg, BID lisinopril, 2.5mg, QD vitamin D2, 1.25mg, QD Prilosec, 20mg, QD oxycodone, PRN
|
8 | $765.00 | |
| 73417 | Sickle Cell Disease/Anemia | 10M | African American | 23 | Female | United States (US) |
hydroxyurea 2000mg, QD- started 2017 Vitamin D/QD Vitamin C/QD Morphine 15mg PRN pain Folic Acid 1 mg QD
|
2 | $765.00 | |
| 71529 | Sickle Cell Disease/Anemia | 30M | African American | 33 | Female | United States (US) |
Folic Acid 1mg QD Entresto 51-49 mg BID Hydroxyurea 500mg/1000mg alternating daily Lopressor 25 mg BID Daily vitamin spironolactone 12.5mg QD Prilosec 40mg QD Farxiga 10 mg QD
|
1 | ||
| 69891 | Sickle Cell Disease/Anemia | 10M | African American | 42 | Female | United States (US) |
Hydroxyurea 1500mg QD Folic Acid/1mg/QD Hydromorphone/8mg/PRN Oxycontin/30mg/PRN Acetaminophen/325mg/PRN Lidocaine 4% adhesive/PRN tizanidine/4mg/QD Aspirin/81mg/QD Cholecalciferol/1250mcg/QW lisinopril/5mg/QD
|
8 | $765.00 | |
| 68871 | Sickle Cell Disease/Anemia | 10M | African American | 37 | Female | United States (US) |
Deferasirox 180 mg QD
|
3 | $765.00 | |
| 67983 | Sickle Cell Disease/Anemia | 10M | African American | 30 | Female | United States (US) |
Hydroxyurea 500 mg TID Singulair 10 mg QD Folic Acid 1 mg QD Albuterol inh PRN
|
4 | $765.00 | |
| 69901 | Sickle Cell Disease/Anemia | 10M | African American | 35 | Male | United States (US) |
Hydroxyurea/1500mg/QD Gabapentin/300mg/6 a day Tizanidine/4mg/QD Acetaminophen/300mg/PRN Ibuprofen/400mg/PRN Vitamin D2/1.25mg/QW Folic Acid/1mg/QD Colace/100mg/QD Senna/8.6mg/QD Bupropion/300mg/QD Albuterol/MDI/PRN Symbicort/MDI/BID
|
2 | $765.00 |
High-Quality Sickle Cell Disease PBMC for Research
Sickle Cell Disease Human PBMC products are sourced from donors clinically diagnosed with sickle cell disease (SCD) and processed under stringent conditions to support research. These cryopreserved peripheral blood mononuclear cells (PBMCs) enable studies to investigate potential therapeutic interventions targeting immune pathways in SCD.
Product Features
- Research Use Only (RUO), cryopreserved PBMCs
- Clinically confirmed SCD donors
- Available in cell counts ranging from 5 million to 2 billion
- Processed within 24 hours of collection
- Stored using CryoStor® CS10 freezing media
- IRB-approved protocols and electronic informed consent
- Screen LeukoLot™ available prior to bulk orders
De-identified Donor Data
- Verified SCD diagnosis
- Donor demographics: age, sex assigned at birth, race/ethnicity
- Self-reported allergies and infectious disease history
- Additional SCD-specific data available upon request
Applications
- Biomarker discovery and validation
- Drug screening and therapeutic development
- Immune pathway analysis in Sickle Cell Disease pathophysiology
- Transcriptomic and proteomic profiling
Quality and Compliance
- IRB-approved collections and protocols
- 21 CFR Part 11 – compliant e-consent system
- HIPAA-compliant donor data protection
Ordering & Shipping
Sickle Cell Disease PBMC samples are shipped on dry ice and available in custom aliquots. For international orders or regulatory requirements, please contact learnmore@sanguinebio.com to confirm documentation and compliance needs.
Protocols & Documentation
-
Download
PBMC Isolation from Whole Blood
Standard operating procedure for isolating peripheral blood mononuclear cells from whole blood using density-gradient separation.
-
Download
Immune Cell Isolation
Guidelines for isolating immune cell populations with validated enrichment steps, purity checkpoints, and documentation.
-
Download
Choosing the Right PBMC Configuration
Reference guide comparing PBMC formats, cryopreservation states, and study-fit recommendations for your application.
-
Download
Thawing Cryopreserved PBMC
Validated thawing protocol to recover viable cryopreserved PBMCs while minimizing activation and loss of function.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
Sickle Cell Disease Publications
PBMC
Frequently Asked Questions
1 Answer
Electronic medical records are an option to be included with the PBMC sample, as well as, flow cytometry and other phenotypic testing.
1 Answer
YES – we can often accommodate treatment-naive samples including various cancers, and you can specify immunosupression status or other requirements in the I/E criteria.
1 Answer
Self-reported infectious disease testing is always available and some of our products have additional testing.
1 Answer
HLA-typing is available for some of our PBMC products.
1 Answer
YES to both – Unique donors can be specified, and multiple vials from the same donor can be arranged. You can specify these requirements when ordering.
1 Answer
Healthy PBMCs achieve over 90% vialbity post-thaw. Although our disease-state PBMCs are processed with same stringent SOP, there is more variability depending upon disease. Learn more about our post thaw viability here. https://sanguinebio.com/pbmc-viability-quality-assurance/
Ask a Question
Need a custom PBMC cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.